HEICO's actual results may differ materially from those expressed in or implied by those forward-looking statements. Factors ...

Thank you for joining us today. Throughout the year, we effectively leveraged Mission's differentiated global sourcing ...

GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...